After spending 24 years at Accenture helping clients solve complex business challenges through strategy, process improvement, and technology-enable transformation, Rich joined CURE’s staff to work on strategic planning and execution, organizational growth and innovation, and support the further development and strengthening of partnerships. Rich became involved in the pediatric cancer community at a young age when his sister was diagnosed with Astrocytoma and again when Rich’s son Declan was diagnosed with Acute Lymphoblastic Leukemia at age 6. Rich spent three years on CURE’s Board of Directors shortly after the end of Declan’s cancer treatments.
“I am thrilled to join the CURE team during a critical and exciting time in the discovery of new treatments aimed at ending childhood cancer and improving the quality of living for the children treated for this horrible disease.”
